Literature DB >> 20499240

Embryonal tumor with abundant neuropil and true rosettes (ETANTR): a new distinctive variety of pediatric PNET: a case-based update.

Belén Ferri Niguez1, Juan F Martínez-Lage, María-José Almagro, José-Luis Fuster, Cristina Serrano, María Amparo Torroba, Joaquín Sola.   

Abstract

BACKGROUND: Embryonal central nervous system (CNS) tumors are currently classified into three types: medulloblastoma, atypical rhabdoid/teratoid tumors, and primitive neuroectodermal tumor (PNET). A distinctive subtype of PNET called "embryonal tumor with abundant neuropil and true rosettes" (ETANTR) was reported in 2000. DISCUSSION: ETANTR is a recently described variety of PNET that combines microscopic features of neuroblastoma and ependymoblastoma, demonstrating areas of fine fibrillary neuropil intermingled with cellular zones and ependymoblastic rosettes. It has been suggested that this neoplasm should be considered as a separate entity. ETANTR is an eminently pediatric tumor that has been reported exclusively in children younger than 4 years. ILLUSTRATIVE CASES: A 9-month-old girl underwent subtotal resection of a brainstem neoplasm. A 23-month-old girl was submitted to surgery for a frontoparietal tumor. In both instances, the histopathological diagnosis confirmed ETANTR. Both children were treated with chemotherapy and one with radiotherapy. Death in both patients occurred after a mean period of 10 months.
CONCLUSIONS: By reporting these two new instances of ETANTR, we want to contribute to the knowledge of this highly malignant CNS embryonal neoplasm that occurs only in young children, given its present lethal prognosis, the scarcity of reported cases, and the lack of treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20499240     DOI: 10.1007/s00381-010-1179-x

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  11 in total

1.  Ependymoblastoma: dear, damned, distracting diagnosis, farewell!*.

Authors:  Alexander R Judkins; David W Ellison
Journal:  Brain Pathol       Date:  2008-12-17       Impact factor: 6.508

2.  Embryonal tumor with abundant neuropil and true rosettes: morphological, immunohistochemical, ultrastructural and molecular study of a case showing features of medulloepithelioma and areas of mesenchymal and epithelial differentiation.

Authors:  Anna Maria Buccoliero; Francesca Castiglione; Duccio Rossi Degl'Innocenti; Alessandro Franchi; Milena Paglierani; Massimiliano Sanzo; Valentina Cetica; Laura Giunti; Iacopo Sardi; Lorenzo Genitori; Gian Luigi Taddei
Journal:  Neuropathology       Date:  2009-06-25       Impact factor: 1.906

3.  Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes.

Authors:  C G Eberhart; D J Brat; K J Cohen; P C Burger
Journal:  Pediatr Dev Pathol       Date:  2000 Jul-Aug

4.  Embryonal tumor with abundant neuropil and true rosettes. A new entity or only variations of a parent neoplasms (PNETs)? This is the dilemma.

Authors:  M La Spina; S Pizzolitto; M Skrap; A Nocerino; G Russo; A Di Cataldo; G Perilongo
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

5.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

Authors:  Stefan Rutkowski; Udo Bode; Frank Deinlein; Holger Ottensmeier; Monika Warmuth-Metz; Niels Soerensen; Norbert Graf; Angela Emser; Torsten Pietsch; Johannes E A Wolff; Rolf D Kortmann; Joachim Kuehl
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Posterior fossa tumor in a 2 year-old girl.

Authors:  Turki Omar Al-Hussain; Mohammad Anas Dababo
Journal:  Brain Pathol       Date:  2009-04       Impact factor: 6.508

7.  Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor.

Authors:  Marco Gessi; Felice Giangaspero; Libero Lauriola; Marina Gardiman; Bernd W Scheithauer; William Halliday; Cynthia Hawkins; Marc K Rosenblum; Peter C Burger; Charles G Eberhart
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

8.  Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes.

Authors:  Stefan Pfister; Marc Remke; Mirco Castoldi; Alfa H C Bai; Martina U Muckenthaler; Andreas Kulozik; Andreas von Deimling; Armin Pscherer; Peter Lichter; Andrey Korshunov
Journal:  Acta Neuropathol       Date:  2008-12-05       Impact factor: 17.088

9.  Embryonal tumor with abundant neuropil and true rosettes (ETANTR): report of a case with prominent neurocytic differentiation.

Authors:  Christopher Dunham; Ella Sugo; Vivienne Tobias; Edward Wills; Arie Perry
Journal:  J Neurooncol       Date:  2007-02-28       Impact factor: 4.506

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  8 in total

1.  CT and Multimodal MR Imaging Features of Embryonal Tumors with Multilayered Rosettes in Children.

Authors:  V Dangouloff-Ros; A Tauziède-Espariat; C-J Roux; R Levy; D Grévent; F Brunelle; A Gareton; S Puget; K Beccaria; T Blauwblomme; J Grill; C Dufour; P Varlet; N Boddaert
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 2.  Evaluation of the good tumor response of embryonal tumor with abundant neuropil and true rosettes (ETANTR).

Authors:  Petra Mozes; Péter Hauser; Tibor Hortobágyi; Gábor Benyó; István Peták; Miklós Garami; Adrienne Cserháti; Katalin Bartyik; László Bognár; Zoltán Nagy; Eszter Turányi; Katalin Hideghéty
Journal:  J Neurooncol       Date:  2015-09-15       Impact factor: 4.130

3.  Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Authors:  Kayleen Bailey; Neeta Pandit-Taskar; John L Humm; Pat Zanzonico; Stephen Gilheeney; Nai-Kong V Cheung; Kim Kramer
Journal:  J Neurooncol       Date:  2019-03-16       Impact factor: 4.130

4.  The role of CD133+ cells in a recurrent embryonal tumor with abundant neuropil and true rosettes (ETANTR).

Authors:  Shawn L Hervey-Jumper; David B Altshuler; Anthony C Wang; Xiaobing He; Cormac O Maher; Patricia L Robertson; Hugh J L Garton; Xing Fan; Karin M Muraszko; Sandra Camelo-Piragua
Journal:  Brain Pathol       Date:  2013-08-12       Impact factor: 6.508

Review 5.  The clinical implications of medulloblastoma subgroups.

Authors:  Paul A Northcott; Andrey Korshunov; Stefan M Pfister; Michael D Taylor
Journal:  Nat Rev Neurol       Date:  2012-05-08       Impact factor: 42.937

6.  Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.

Authors:  Andrey Korshunov; Dominik Sturm; Marina Ryzhova; Volker Hovestadt; Marco Gessi; David T W Jones; Marc Remke; Paul Northcott; Arie Perry; Daniel Picard; Marc Rosenblum; Manila Antonelli; Eleonora Aronica; Ulrich Schüller; Martin Hasselblatt; Adelheid Woehrer; Olga Zheludkova; Ella Kumirova; Stephanie Puget; Michael D Taylor; Felice Giangaspero; V Peter Collins; Andreas von Deimling; Peter Lichter; Annie Huang; Torsten Pietsch; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2013-12-14       Impact factor: 17.088

7.  Radiation for ETMR: Literature review and case series of patients treated with proton therapy.

Authors:  Sergio Jaramillo; David R Grosshans; Nancy Philip; Ali Varan; Canan Akyüz; Mary Frances McAleer; Anita Mahajan; Susan L McGovern
Journal:  Clin Transl Radiat Oncol       Date:  2018-11-07

Review 8.  Embryonal tumor with abundant neuropil and true rosettes: an autopsy case-based update and review of the literature.

Authors:  Dariusz Adamek; Kolawole D Sofowora; Magdalena Cwiklinska; Izabela Herman-Sucharska; Stanislaw Kwiatkowski
Journal:  Childs Nerv Syst       Date:  2013-01-29       Impact factor: 1.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.